StockData
Actuate Therapeutics, Inc. logo

Actuate Therapeutics, Inc. (ACTU) shareholders

ACTUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$0.29−0.01 (-3.61%)

Close on Nov 13, 2026Market cap $6.85MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
56.3%
14M of 24M shares
Institutional holders
64
18 new, 14 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
1 buys · 1 sales
Net sold $1.57M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Aaron G.L. Fletcher
Joint filing with Bios Advisors Gp, LLC (49.50%), Bios Capital Management, LP (49.50%) and 9 more
10,267,23249.80%13D (active) amendmentJun 27, 2025
Brendan O'Neil
Joint filing with Hexstone Capital LLC (7.70%)
4,225,3527.70%13G (passive)Oct 27, 2026
Voss Capital, LP
Joint filing with Cocke Travis W. (7.70%)
1,814,2637.70%13G (passive) amendmentMar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ACTUValueChange% of portfolio
BIOS Capital Management, LP10,049,99641.85%$15.38M–36.90%
Voss Capital, LLC1,725,0007.18%$2.64M–0.12%
Vanguard Capital Management LLC393,4331.64%$601.95K−7,0960.00%
Aqr Capital Management LLC127,4930.53%$195.06K+100,3840.00%
Geode Capital Management, LLC112,5540.47%$172.21K−115,7770.00%
Texas Capital Bank Wealth Management Services Inc102,6120.43%$157.00K+8,0200.01%
Palogic Value Management, L.P.100,0000.42%$153.00K–0.05%
Millennium Management LLC96,6840.40%$147.93KNew0.00%
BlackRock, Inc.90,0350.37%$137.75K−337,1180.00%
ABS Investment Management LLC73,1860.30%$111.98KNew0.07%
ABS Direct Equity Fund LLC73,1860.30%$111.98K+23,1860.07%
Vanguard Fiduciary Trust Co54,4970.23%$83.38K−8,0950.00%
Rock Creek Group, LP39,2630.16%$60.07K–0.01%
Jane Street Group, LLC39,1320.16%$59.87KNew0.00%
HighTower Advisors, LLC36,4610.15%$55.79KNew0.00%
Goldman Sachs Group Inc35,4980.15%$54.31K+23,0900.00%
Sfmg, LLC33,0000.14%$50.49K–0.00%
Susquehanna International Group, Llp28,1820.12%$43.12KNew0.00%
Bridgeway Capital Management, LLC23,4820.10%$35.93K−7,5000.00%
State Street Corp21,8500.09%$33.43K−44,1800.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20266414M56.3%18 / 1820 / 141M1M
Q1 20266114M57.7%22 / 2010 / 41M0M
Q4 20254513M54.6%8 / 219 / 61M0M
Q3 20254312M50.1%7 / 1711 / 21M0M
Q2 20253811M46.7%21 / 122 / 81M0M
Q1 20252510M43.3%9 / 101 / 30M0M
Q4 20241910M42.1%13 / 12 / 410M0M
Q3 2024100M1.6%10 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

59 funds held ACTU in Q1 2026, 70% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ACTUValue% of fundAs of
Vanguard Total Stock Market Index Fund287,3851.20%$439.70K0.00%Jun 30, 2026
Vanguard Extended Market Index Fund106,0480.44%$162.25K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund51,9190.22%$104.88K0.00%May 31, 2026
Vanguard Russell 2000 Index Fund48,3950.20%$97.76K0.00%May 31, 2026
iShares Micro-Cap ETF38,2300.16%$58.49K0.00%Jun 30, 2026
Ultra-Small Company Market Fund23,4820.10%$35.93K0.02%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund15,8850.07%$32.09K0.00%May 31, 2026
Fidelity Total Market Index Fund13,5910.06%$27.45K0.00%May 31, 2026
iShares Russell 2000 ETF13,2490.06%$20.27K0.00%Jun 30, 2026
Fidelity Series Total Market Index Fund12,2520.05%$24.75K0.00%May 31, 2026
Vanguard Russell 2000 Growth Index Fund8,8450.04%$17.87K0.00%May 31, 2026
iShares Russell 2000 Growth ETF5,5060.02%$8.42K0.00%Jun 30, 2026
Small Cap Index Fund5,4900.02%$11.09K0.00%May 31, 2026
Bridge Builder Small/Mid Cap Growth Fund1,7380.01%$2.66K0.00%Jun 30, 2026
1290 VT Micro Cap Portfolio1,7000.01%$2.60K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Daniel M. SchmittPresident, CEO and Director1,073,3004.47%Oct 29, 2026
Andrew Paul MazarChief Operating Officer127,2500.53%Apr 1, 2026
Paul J. LytleChief Financial Officer––Apr 1, 2026
Kairos Venture Investments, LLCDirector––Nov 2, 2026
Kairos Venture Partners II, L.P.Director––Nov 2, 2026
Kairos Venture Opportunities I, L.P.Director––Nov 2, 2026
SPV Fund LLC KairosDirector––Nov 2, 2026
Kairos-Actuate SPV, L.P.Director2,487,47410.36%Nov 2, 2026
James T. DemetriadesDirector––Nov 2, 2026
Todd S. ThomsonDirector2,354,3449.80%Nov 2, 2026
BIOS Fund II NT, LPDirector, 10% owner––Oct 30, 2026
BIOS Fund I, LPDirector, 10% owner––Oct 30, 2026
BIOS Fund II, LPDirector, 10% owner10,257,42942.71%Oct 30, 2026
BIOS Fund I QP, LPDirector, 10% owner––Oct 30, 2026
BIOS Fund II QP, LPDirector, 10% owner9,147,21438.09%Oct 30, 2026
BIOS Fund III, LPDirector, 10% owner––Oct 30, 2026
BIOS Fund III QP, LPDirector, 10% owner––Oct 30, 2026
BIOS Fund III NT, LPDirector, 10% owner––Oct 30, 2026
Bios Clinical Opportunity Fund, LPDirector, 10% owner1,472,7976.13%Oct 30, 2026
BIOS Actuate Co-Invest II, LPDirector, 10% owner––Oct 30, 2026
Bios Actuate Co-Invest III, LPDirector, 10% owner231,3770.96%Oct 30, 2026
BIOS Actuate Co-Invest I, LPDirector, 10% owner10,196,45642.46%Oct 30, 2026
Bios 2024 Co-Invest, LPDirector, 10% owner125,0000.52%Oct 30, 2026
Aaron G.L. FletcherDirector, 10% owner––May 22, 2026
Amy L. RonnebergDirector––May 22, 2026
Roger SawhneyDirector––May 22, 2026
Dan ZabrowskiDirector76,3480.32%May 22, 2026
Jason A. KeyesDirector––May 22, 2026
Martin H. Huber Jr.Director––May 22, 2026
BIOS Advisors GP, LLCDirector, 10% owner––Jun 30, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Daniel M. Schmitt
President, CEO and Director
Oct 28, 2026Buy+140,844$0.35$50.00K442,560
Daniel M. Schmitt
President, CEO and Director
Aug 14, 2026Option exercise+272,056––422,237
Daniel M. Schmitt
President, CEO and Director
Aug 14, 2026Tax withholding−120,521$1.01$121.73K301,716
Daniel M. Schmitt
President, CEO and Director
Feb 13, 2026Option exercise+272,055––272,055
Daniel M. Schmitt
President, CEO and Director
Feb 13, 2026Tax withholding−121,874$4.33$527.71K150,181
Todd S. Thomson
Director, 10% owner
Jan 5, 2026Sale−280,000$5.80$1.62M904,795
Bios Equity COF, LP
Director, 10% owner
Jun 27, 2025Buy+71,428$7.00$500.00K196,428
BIOS Actuate Co-Invest I, LP
Director, 10% owner
Jun 27, 2025Buy+71,428$7.00$500.00K196,428
BIOS Fund II, LP
Director, 10% owner
Jun 27, 2025Buy+71,428$7.00$500.00K196,428
BIOS Capital Management, LP
Director, 10% owner
Aug 14, 2024Sale−17,361$8.00$138.89K980,433
BIOS Capital Management, LP
Director, 10% owner
Aug 14, 2024Sale−5,314$8.00$42.51K300,143
BIOS Capital Management, LP
Director, 10% owner
Aug 14, 2024Sale−2,324$8.00$18.59K131,248
Bios Clinical Opportunity Fund, LP
Director, 10% owner
Aug 14, 2024Sale−5,314$8.00$42.51K300,143
Bios Clinical Opportunity Fund, LP
Director, 10% owner
Aug 14, 2024Sale−17,361$8.00$138.89K980,433
Bios Clinical Opportunity Fund, LP
Director, 10% owner
Aug 14, 2024Sale−2,324$8.00$18.59K131,248
BIOS Fund II, LP
Director, 10% owner
Aug 14, 2024Sale−17,361$8.00$138.89K980,433
BIOS Fund II, LP
Director, 10% owner
Aug 14, 2024Sale−5,314$8.00$42.51K300,143
BIOS Fund II, LP
Director, 10% owner
Aug 14, 2024Sale−2,324$8.00$18.59K131,248
Kairos-Actuate SPV, L.P.
Director
Aug 14, 2024Sale−18,750$8.00$150.00K1,184,795
Kairos-Actuate SPV, L.P.
Director
Aug 14, 2024Option exercise+28,464$5.27$150.01K1,203,545
Kairos-Actuate SPV, L.P.
Director
Aug 14, 2024Conversion+49,984––321,781
Kairos-Actuate SPV, L.P.
Director
Aug 14, 2024Conversion+24,138––254,735
Kairos-Actuate SPV, L.P.
Director
Aug 14, 2024Conversion+132,908––271,797
Kairos-Actuate SPV, L.P.
Director
Aug 14, 2024Conversion+69,445––1,175,081
Kairos-Actuate SPV, L.P.
Director
Aug 14, 2024Conversion+1,058,318––1,105,636
Kairos-Actuate SPV, L.P.
Director
Aug 14, 2024Conversion+726,163––726,163
Kairos-Actuate SPV, L.P.
Director
Aug 14, 2024Conversion+138,889––138,889
Kairos-Actuate SPV, L.P.
Director
Aug 14, 2024Conversion+230,597––230,597
Kairos-Actuate SPV, L.P.
Director
Aug 14, 2024Conversion+146,870––873,033
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Buy+375,000$8.00$3.00M1,259,427
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Option exercise+3,528$5.27$18.59K133,572
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Sale−17,361$9.00$156.25K980,433
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Option exercise+26,355$5.27$138.89K997,794
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Sale−5,314$9.00$47.83K300,143
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Option exercise+8,068$5.27$42.52K305,457
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+573,394––573,394
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+78,267––404,814
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+484,638––2,506,667
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+74,202––383,791
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+2,094,650––2,094,650
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+326,547––326,547
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+2,022,029––2,022,029
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+309,589––309,589
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+44,559––130,044
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+332,867––971,439
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+101,900––297,389
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+147,047––300,749
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+23,628––85,485
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+176,499––638,572
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+54,032––195,489
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+153,702––153,702
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+61,857––61,857
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+462,073––462,073
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+141,457––141,457
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+307,538––307,538
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+525,797––525,797
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Buy+125,000$8.00$1.00M125,000
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Sale−2,324$9.00$20.92K131,248
BIOS Equity Partners III, LP
Director, 10% owner
Aug 14, 2024Conversion+884,427––884,427
BIOS Fund II QP, LP
Director, 10% owner
Aug 14, 2024Conversion+61,857––61,857

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
16.24%
1M shares short
Days to cover
2.1
At 1M shares a day
Change since last report
-30.5%
From 2M shares
Short volume, 20 days
48.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Actuate Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 95,859 shares on Oct 7, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Kairos Venture Partners II, L.P.
Affiliate
Dec 11, 2025280,000$2.13MDec 11, 2025Private Investment, Pre-IPO

See a number that looks wrong?